In 2017, CytomX entered into a strategic immuno-oncology collaboration with Amgen to co-develop T cell engaging bispecific therapeutics. The companies are co-developing a CytomX Probody T cell engaging bispecific against the epidermal growth factor receptor (EGFR), a highly validated oncology target expressed on multiple human cancer types, with CytomX leading early development. Amgen will lead later development and commercialization with global late-stage development costs shared between the two companies. CytomX is eligible to receive development, regulatory and commercial milestones for the EGFR program.
Amgen will lead global commercial activities with CytomX able to opt into a profit share in the U.S. and receive tiered, double-digit royalties on net product sales outside of the U.S. Existing targets in CytomX discovery, preclinical research or clinical development are not eligible for selection by Amgen, and CytomX’s CX-072, CX-2009, and CX-188 programs remain wholly owned.
Amgen also receives exclusive worldwide rights to develop and commercialize up to three additional, undisclosed targets. Should Amgen ultimately pursue all of these targets, CytomX will be eligible to receive additional upfront and milestone payments and high single-digit to mid-double digit royalty payments on any resulting products. CytomX also receives the rights from Amgen to an undisclosed preclinical T cell engaging bispecific program. Amgen is eligible to receive milestones and royalty payments on any resulting products from this CytomX program.